Tag Archives: bad-request

Sucampo Stock Hits High On EPS, But CVS Nixes Drug

Specialty drugmaker Sucampo Pharmaceuticals (SCMP) beat Q2 expectations and raised its guidance early Wednesday, sending the stock to a new high in early trading. It pulled back later, however, possibly because word got out that its sole marketed drug is being excluded from CVS’ (CVS) preferred formulary next year. Sucampo reported earnings of 21 cents a share, up from just 4 cents in the year-earlier quarter and 6 cents above analysts’ consensus,

Zynerba Pharmaceuticals Pops On First Day Of Trading

Zynerba Pharmaceuticals (ZYNE) got a strong start on its first day of trading Wednesday, with an initial public offering that raised $42 million. Zynerba is developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. It’s looking to treat central nervous system disorders with treatments derived from cannabis. The company late Tuesday priced 3 million shares at 14, the midpoint of its expected

SolarCity Breaks Into Mexican Solar Market

Between now and 2020, Marco Krapels visualizes a “several-gigawatt (solar) market” in Mexico. San Mateo, Calif.-based SolarCity (SCTY) wants a piece of that. “Mexico is a very exciting market for us,” Krapels, SolarCity senior vice president of strategy, told IBD. “It’s not only our neighbor … but Mexico is an important entry into Latin America as well. It’s a mass opportunity.” To that end, SolarCity announced Wednesday it recently penned a